Materials and Methods: Patients completed the PTNS treatment with tapering protocols applied for 6, 9, 12, and 24 months. After 12 weeks of therapy, PTNS was applied at 14 day intervals for 3, at 21 day intervals for 3, and at 28 day intervals for 3 months. The patients completed a 3-day voiding diary at the 3rd, 6th, 9th, 12th, and 24th months. The patients were requested to complete validated questionnaires (ICIQ-SF, OAB-V8, OAB-q SF) within 3-month intervals thereafter during their enrolment in the study.

Results: The mean age of 57 patients who completed the PTNS treatment protocol and were included in the study was 42.6 ± 8.2 (23-64) years. Fifteen (26.3%) patients were male and 42 (73.6%) were female. The improvements for all voiding diary parameters were significant at 3rd, 6th, 9th, 12th, and 24th months when compared with the baseline. After 24 months, the daily frequencies of voiding decreased by 6.7 (p<0.001), urge urinary incontinence by 4.2 (p<0.001), urge by 8.4 (p<0.001), nocturia by 2.2 (p<0.001), and the mean voiding volume increased by 85.8 cc (p<0.001). No treatment-related side effects were reported in the patients for 24 months.

Conclusion: This study showed that the symptoms of the patients with NOAB due to MS improved after 24 months of PTNS treatment.